We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cognate Therapeutics Changes Name to Cognate BioServices

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Cognate Therapeutics, Inc. has announced it has changed its name to Cognate BioServices, Inc. A name change better reflects the company's focus and achievements in providing product development and cGMP manufacturing services to organizations in the regenerative medicine space working on cell therapies.

President and Chief Operating Officer Dr. Alan K. Smith said, "The name Cognate BioServices emphasizes our business focus on the provision of services related to the development and cGMP manufacturing of cell-based therapeutics."

"We are taking advantage of our unique and extensive experience base and facilities which allow us to provide a spectrum of services, ranging from preclinical process development and scale-up, through complete cGMP manufacturing and quality control."